REFERENCES
- Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, random-ized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17(18):2603–2614.
- Squires K, Iaggarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5):1011–1019.
- Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in pa-tients experiencing multiple virological failures. AIDS. 2005;19(7):685–694.
- Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292(2):251–265.
- Gibbons S, Robinson L, Dickinson L, et al. Therapeutic drug monitoring of atazanavir in routine clinical setting in UK. In: Program and abstracts of the International Con-gress on Drug Therapy in HIV; 2004; Glasgow, Scotland.
- Gonzalez D, Bonora S, Canta F, et al. Atazanavir C trough is associated with efficacy and safety: definition of thera-peutic range. In: Program and abstracts of the 12th Confer-ence on Retroviruses and Opportunistic Infections; 2005; Boston.
- Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive indi-viduals receiving highly active antiretroviral therapy. J Antimicrob Chemother. 2005;56(2):380–387.
- Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr. 2004;36(2):684–692.
- Jeganathan S, Smith D, Gold J. Early clinical experience with atazanavir in treatment experienced patients. Sexual Health. 2006;3:33–35.
- Gateau E, Tournier N, Dupuis A, Le Moal G, Venisse N. Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatog-raphy. J Pharm Biomed AnaL 2005;39(3-4):791–795.
- Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1975.
- Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pre-treated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48(6):2091–2096.
- Bristol-Meyers Squibb Company. Reyataz (Atazanavir Sul-fate) Product Information Guide; 2003.
- Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 200115(1):71–75.
- Boyd MA, Siangphoe U, Ruxrungtham K, et al. Indinavir/ ritonavir 800/100 mg bid and efavirenz 600 mg qd in pa-tients failing treatment with combination nucleoside re-verse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Med. 2005;6(6):410–420.
- Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15(18):2441–2444.
- Barrios A, Rendon AL, Gallego O, et al. Predictors of viro-logical response to atazanavir in protease inhibitor-experi-enced patients. HIV Clin Trials. 2004;5(4):201–205.